v3.26.1
Collaboration and License Agreements (Tables)
6 Months Ended
Jun. 30, 2026
Organization, Consolidation and Presentation of Financial Statements [Abstract]  
Schedule of Revenue from Collaboration Partners

The following table summarizes the revenue recognized from collaboration partners (in thousands):

 

 

Three Months Ended June 30,

 

 

Six Months Ended June 30,

 

 

2026

 

 

2025

 

 

2026

 

 

2025

 

Prevail

 

$

1,918

 

 

$

4,778

 

 

$

4,151

 

 

$

21,568

 

Sanofi

 

 

 

 

120

 

 

 

 

 

455

 

Total Revenue

 

$

1,918

 

 

$

4,898

 

 

$

4,151

 

 

$

22,023

 

Summary of Contract Liabilities

The following table presents changes in the Company’s total contract liabilities for the six months ended June 30, 2026 and 2025(in thousands):

 

 

Balance at
December 31, 2025

 

 

Additions

 

Revenue
Recognized

 

 

Balance at
June 30, 2026

 

Contract Liabilities;

 

 

 

 

 

 

 

 

 

 

 

Deferred revenue

 

$

41,023

 

 

$ -

 

$

(1,850

)

 

$

39,173

 

 

 

Balance at
December 31, 2024

 

 

Additions

 

Revenue
Recognized

 

 

Balance at
June 30, 2025

 

Contract Liabilities;

 

 

 

 

 

 

 

 

 

 

 

Deferred revenue

 

$

72,419

 

 

$ -

 

$

(11,880

)

 

$

60,539